These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 7089477)

  • 21. Current concepts in the overall management of thalassemia.
    Propper RD
    Ann N Y Acad Sci; 1980; 344():375-83. PubMed ID: 6930877
    [No Abstract]   [Full Text] [Related]  

  • 22. Mössbauer spectroscopy study of iron overloaded livers.
    Rimbert JN; Dumas F; Kellershohn C; Girot R; Brissot P
    Biochimie; 1985 Jun; 67(6):663-8. PubMed ID: 4052495
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Iron loading in beta-thalassaemia.
    Cazzola M; Alessandrino P; Barosi G; Orlandi E; Ascari E
    Lancet; 1980 Jan; 1(8161):204. PubMed ID: 6101656
    [No Abstract]   [Full Text] [Related]  

  • 24. Splenectomy, iron overload and liver cirrhosis in beta-thalassemia major.
    Okon E; Levij IS; Rachmilewitz EA
    Acta Haematol; 1976; 56(3):142-50. PubMed ID: 826069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transfusions and erythropoiesis in beta-thalassemia.
    Celada A
    N Engl J Med; 1978 Aug; 299(7):360. PubMed ID: 683271
    [No Abstract]   [Full Text] [Related]  

  • 26. No evidence of cardiac iron in 20 never- or minimally-transfused patients with thalassemia intermedia.
    Origa R; Barella S; Argiolas GM; Bina P; Agus A; Galanello R
    Haematologica; 2008 Jul; 93(7):1095-6. PubMed ID: 18508795
    [No Abstract]   [Full Text] [Related]  

  • 27. New therapeutic targets in transfusion-dependent and -independent thalassemia.
    Cappellini MD; Motta I
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):278-283. PubMed ID: 29222267
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Imbalance of erythropoiesis and iron metabolism in patients with thalassemia.
    Huang Y; Lei Y; Liu R; Liu J; Yang G; Xiang Z; Liang Y; Lai Y
    Int J Med Sci; 2019; 16(2):302-310. PubMed ID: 30745811
    [No Abstract]   [Full Text] [Related]  

  • 29. Iron loading and endocrine functions in nontransfused patients with beta-thalassemia intermedia or sickle-cell thalassemia.
    Flatau E; Resnitzky P; Kauffman N; Harpaz S; Kohn D
    Isr J Med Sci; 1981 Jan; 17(1):22-7. PubMed ID: 7461943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Iron Chelation Therapy as a Modality of Management.
    Aydinok Y
    Hematol Oncol Clin North Am; 2018 Apr; 32(2):261-275. PubMed ID: 29458731
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Evaluation of iron balance in homozygous beta-thalassemia subjects treated with desferrioxamine administered subcutaneously].
    Ferrara M; Galdo Capotorti M; Ponte G; Esposito L
    Pediatria (Napoli); 1983; 91(4):371-7. PubMed ID: 6545400
    [No Abstract]   [Full Text] [Related]  

  • 32. Pathophysiology and treatment of iron overload in thalassemia patients in tropical countries.
    Marx JJ
    Adv Exp Med Biol; 2003; 531():57-68. PubMed ID: 12916781
    [No Abstract]   [Full Text] [Related]  

  • 33. Retrospective epidemiological study of Latin American patients with transfusional hemosiderosis: the first Latin American epidemiological study in iron overload--the RELATH study.
    Lobo C; Angulo IL; Aparicio LR; Drelichman GI; Zanichelli MA; Cancado R;
    Hematology; 2011 Sep; 16(5):265-73. PubMed ID: 21902889
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Iron balance in thalassemia.
    Cazzola M; Finch CA
    Prog Clin Biol Res; 1989; 309():93-100. PubMed ID: 2675109
    [No Abstract]   [Full Text] [Related]  

  • 35. Morbidities in non-transfusion-dependent thalassemia.
    Saliba AN; Taher AT
    Ann N Y Acad Sci; 2016 Mar; 1368(1):82-94. PubMed ID: 27186941
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
    Kontoghiorghe CN; Kontoghiorghes GJ
    Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HFE mutation H63D predicts risk of iron over load in thalassemia intermedia irrespective of blood transfusions.
    Sharma V; Panigrahi I; Dutta P; Tyagi S; Choudhry VP; Saxena R
    Indian J Pathol Microbiol; 2007 Jan; 50(1):82-5. PubMed ID: 17474269
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation between Heart, Liver and Pancreas Hemosiderosis Measured by MRI T2* among Thalassemia Major Patients from Iran.
    Azarkeivan A; Hashemieh M; Shirkavand A; Sheibani K
    Arch Iran Med; 2016 Feb; 19(2):96-100. PubMed ID: 26838079
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Hemosiderosis in thalassemia major. Quantitative study with magnetic resonance (MR)].
    Rossi L; Castriota-Scanderbeg A; Ferrozzi F; Butturini A; Rossi A
    Radiol Med; 1992 Mar; 83(3):237-42. PubMed ID: 1579672
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transfusional hemosiderosis and combined chelation therapy in sickle thalassemia.
    Tsironi M; Polonifi K; Deftereos S; Farmakis D; Andriopoulos P; Moyssakis I; Aessopos A
    Eur J Haematol; 2005 Oct; 75(4):355-8. PubMed ID: 16146544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.